SAN
DIEGO, July 1, 2024 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell
therapy and genetic medicines company advancing differentiated
non-viral treatments for patients with cancer and rare diseases,
today announced that the Company's President and Chief Executive
Officer, Kristin Yarema, Ph.D., will
participate in a virtual fireside chat at the Stifel 2024 Virtual
Cell Therapy Forum on Tuesday, July 9,
2024 at 7:55am PT |
10:55am ET.
A live webcast of the fireside chat will be available on the
Investors & Media Section of Poseida's website,
www.poseida.com. A replay of the webcast will be available for
approximately 90 days following the presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics
is a clinical-stage biopharmaceutical company advancing
differentiated allogeneic cell therapies and genetic medicines with
the capacity to cure certain cancers and rare diseases. The
Company's pipeline includes investigational allogeneic CAR-T cell
therapies for both solid tumors and hematologic cancers as well as
investigational in vivo genetic medicines that address patient
populations with high unmet medical need. The Company's approach is
based on its proprietary genetic editing platforms, including its
non-viral piggyBac® DNA Delivery System, Cas-CLOVER™
Site-Specific Gene Editing System, Booster Molecule and
nanoparticle gene delivery technologies, as well as in-house GMP
cell therapy manufacturing. The Company has formed strategic
collaborations with Roche and Astellas to unlock the promise of
cell therapies for cancer patients. Learn more at
www.poseida.com and connect with Poseida on X and
LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-participation-in-stifels-2024-virtual-cell-therapy-forum-302184670.html
SOURCE Poseida Therapeutics, Inc.
